Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Nov 22;11(11):CD012216.
doi: 10.1002/14651858.CD012216.pub2.

18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Gabriel Martínez  1 , Robin Wm Vernooij, Paulina Fuentes Padilla, Javier Zamora, Xavier Bonfill Cosp, Leon Flicker
Affiliations
Meta-Analysis

18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)

Gabriel Martínez et al. Cochrane Database Syst Rev. .

Abstract

Background: 18F-florbetapir uptake by brain tissue measured by positron emission tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using amyloid biomarkers tests like 18F-florbetapir. These tests, added to the MCI core clinical criteria, might increase the diagnostic test accuracy (DTA) of a testing strategy. However, the DTA of 18F-florbetapir to predict the progression from MCI to Alzheimer's disease dementia (ADD) or other dementias has not yet been systematically evaluated.

Objectives: To determine the DTA of the 18F-florbetapir PET scan for detecting people with MCI at time of performing the test who will clinically progress to ADD, other forms of dementia (non-ADD), or any form of dementia at follow-up.

Search methods: This review is current to May 2017. We searched MEDLINE (OvidSP), Embase (OvidSP), PsycINFO (OvidSP), BIOSIS Citation Index (Thomson Reuters Web of Science), Web of Science Core Collection, including the Science Citation Index (Thomson Reuters Web of Science) and the Conference Proceedings Citation Index (Thomson Reuters Web of Science), LILACS (BIREME), CINAHL (EBSCOhost), ClinicalTrials.gov (https://clinicaltrials.gov), and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (http://www.who.int/ictrp/search/en/). We also searched ALOIS, the Cochrane Dementia & Cognitive Improvement Group's specialised register of dementia studies (http://www.medicine.ox.ac.uk/alois/). We checked the reference lists of any relevant studies and systematic reviews, and performed citation tracking using the Science Citation Index to identify any additional relevant studies. No language or date restrictions were applied to the electronic searches.

Selection criteria: We included studies that had prospectively defined cohorts with any accepted definition of MCI at time of performing the test and the use of 18F-florbetapir scan to evaluate the DTA of the progression from MCI to ADD or other forms of dementia. In addition, we only selected studies that applied a reference standard for Alzheimer's dementia diagnosis, for example, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria.

Data collection and analysis: We screened all titles and abstracts identified in electronic-database searches. Two review authors independently selected studies for inclusion and extracted data to create two-by-two tables, showing the binary test results cross-classified with the binary reference standard. We used these data to calculate sensitivities, specificities, and their 95% confidence intervals. Two independent assessors performed quality assessment using the QUADAS-2 tool plus some additional items to assess the methodological quality of the included studies.

Main results: We included three studies, two of which evaluated the progression from MCI to ADD, and one evaluated the progression from MCI to any form of dementia.Progression from MCI to ADD was evaluated in 448 participants. The studies reported data on 401 participants with 1.6 years of follow-up and in 47 participants with three years of follow-up. Sixty-one (15.2%) participants converted at 1.6 years follow-up; nine (19.1%) participants converted at three years of follow-up.Progression from MCI to any form of dementia was evaluated in five participants with 1.5 years of follow-up, with three (60%) participants converting to any form of dementia.There were concerns regarding applicability in the reference standard in all three studies. Regarding the domain of flow and timing, two studies were considered at high risk of bias. MCI to ADD;Progression from MCI to ADD in those with a follow-up between two to less than four years had a sensitivity of 67% (95% CI 30 to 93) and a specificity of 71% (95% CI 54 to 85) by visual assessment (n = 47, 1 study).Progression from MCI to ADD in those with a follow-up between one to less than two years had a sensitivity of 89% (95% CI 78 to 95) and a specificity of 58% (95% CI 53 to 64) by visual assessment, and a sensitivity of 87% (95% CI 76 to 94) and a specificity of 51% (95% CI 45 to 56) by quantitative assessment by the standardised uptake value ratio (SUVR)(n = 401, 1 study). MCI to any form of dementia;Progression from MCI to any form of dementia in those with a follow-up between one to less than two years had a sensitivity of 67% (95% CI 9 to 99) and a specificity of 50% (95% CI 1 to 99) by visual assessment (n = 5, 1 study). MCI to any other forms of dementia (non-ADD);There was no information regarding the progression from MCI to any other form of dementia (non-ADD).

Authors' conclusions: Although sensitivity was good in one included study, considering the poor specificity and the limited data available in the literature, we cannot recommend routine use of 18F-florbetapir PET in clinical practice to predict the progression from MCI to ADD.Because of the poor sensitivity and specificity, limited number of included participants, and the limited data available in the literature, we cannot recommend its routine use in clinical practice to predict the progression from MCI to any form of dementia.Because of the high financial costs of 18F-florbetapir, clearly demonstrating the DTA and standardising the process of this modality are important prior to its wider use.

PubMed Disclaimer

Conflict of interest statement

Gabriel Martínez has no known conflicts of interest. Leon Flicker has no known conflicts of interest. Robin WM Vernooij has no known conflicts of interest. Paulina Fuentes Padilla has no known conflicts of interest. Javier Zamora has no known conflicts of interest. Xavier Bonfill Cosp has no known conflicts of interest.

Figures

1
1
Study flow diagram.
2
2
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
3
3
Forest plot of tests: 1 MCI to ADD by visual assessment from 2 to less than 4 years of follow‐up, 2 MCI to ADD by visual assessment from 1 to less than 2 years follow‐up, 3 MCI to ADD by SUVR at 1 to less than 2 years follow‐up, 4 MCI to any form of dementia.
1
1. Test
MCI to ADD by visual assessment from 2 to less than 4 years of follow‐up.
2
2. Test
MCI to ADD by visual assessment from 1 to less than 2 years follow‐up.
3
3. Test
MCI to ADD by SUVR at 1 to less than 2 years follow‐up.
4
4. Test
MCI to any form of dementia.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012216

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Doraiswamy 2014 {published data only}
    1. Doraiswamy PM, Clark C, Sperling R, Reiman E, Pontecorvo M, Sabbagh M, et al. Prognostic significance of florbetapir F18 PET imaging in MCI and mormal elderly: final results from a longitudinal multicenter trial. Alzheimer's & Dementia 2011;7 Suppl(4):S108.
    1. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid‐β assessed by florbetapir F 18 PET and 18‐month cognitive decline: a multicenter study. Neurology 2012;79(16):1636‐44. - PMC - PubMed
    1. Doraiswamy PM, Sperling RA, Johnson K, Reiman EM, Wong TZ, Sabbagh MN, et al. Florbetapir F 18 amyloid PET and 36‐month cognitive decline: a prospective multicenter study. Molecular Psychiatry 2014;19(9):1044‐51. - PMC - PubMed
    1. Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer's & Dementia 2013;9 Suppl(5):S72‐83. - PMC - PubMed
    1. NCT00857506. Observational study of cognitive outcomes for subjects who have had prior PET amyloid imaging With Florbetapir F 18 (18F‐AV‐45). https://clinicaltrials.gov/show/NCT00857506 (first received 6 March 2009).
Kawas 2013 {published data only}
    1. Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ, Joshi AD, et al. Amyloid imaging and cognitive decline in nondemented oldest‐old: the 90+ study. Alzheimer's & Dementia 2013;9(2):199‐203. - PMC - PubMed
Schreiber 2015 {published data only}
    1. ADNI 2 PET Technical Procedures Manual AV‐45 (Florbetapir F 18) & FDG. adni.loni.usc.edu/wp‐content/uploads/2010/05/ADNI2_PET_Tech_Manual_01420... (accessed prior to 12 October 2017).
    1. ADNI‐GOPET Technical Procedures Manual AV‐45 & FDG. adni.loni.usc.edu/wp‐content/uploads/2010/05/ADNIGO_PET_Tech_Manual_0114... (accessed prior to 12 October 2017).
    1. Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2). www.adni‐info.org/Scientists/doc/ADNI2_Procedures_Manual_20130624.pdf (accessed prior to 12 October 2017).
    1. Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity (ADNI‐GO). www.adni‐info.org/Scientists/doc/ADNI_GO_Procedures_Manual_06102011.pdf (accessed prior to 12 October 2017).
    1. NCT01078636. Alzheimer's disease neuroimaging initiative grand opportunity (ADNI‐GO). clinicaltrials.gov/show/NCT01078636 (first received 2 March 2010).

References to studies excluded from this review

Altomare 2016 {published data only}
    1. Altomare D, Festari C, Ferrari C, Muscio C, Padovani A, Frisoni GB, et al. Brain amyloidosis and cognitive decline in MCI: 12‐month follow‐up. Alzheimer's & Dementia 2016;12(7 Supplement):P16‐P17.
Apostolova 2016 {published data only}
    1. Apostolova L, Goukasian N, Do T, Grotts J, Ringman J, Elashoff D. Effect of brain amyloidosis on the emergence of neuropsychiatric behaviors in MCI over time. Neurology 2016;86 Suppl 16:P2.232.
Brendel 2014 {published data only}
    1. Brendel M, Hoegenauer M, Delker A, Bartenstein P, Rominger A. Longitudinal amyloid PET in mild cognitive impaired patients. Journal of Nuclear Medicine 2014;55 Suppl 1:193.
Brendel 2015 {published data only}
    1. Brendel M, Högenauer M, Delker A, Sauerbeck J, Bartenstein P, Seibyl J, et al. Improved longitudinal [(18)F]‐AV45 amyloid PET by white matter reference and VOI‐based partial volume effect correction. NeuroImage 2015;108:450‐9. - PubMed
Cheewakriengkrai 2014 {published data only}
    1. Cheewakriengkrai L, Manitsirikul S, Mohades S, Wang S, Shin M, Benedet AL, et al. Neurodegeneration associated with longitudinal changes of abeta1‐42 and fibrillary amyloid. Alzheimer's & Dementia 2014;10 Suppl(4):839‐40.
Chen 2015a {published data only}
    1. Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, et al. Improved power for characterizing longitudinal amyloid‐beta PET changes and evaluating amyloid‐modifying treatments with a cerebral white matter reference region. Journal of Nuclear Medicine 2015;56(4):560‐66. - PubMed
Chen 2015b {published data only}
    1. Chen X, Wang R, Gao R, Cao H, Wong D, Zhou Y. Evaluation of the diagnostic value of FDG and amyloid PET imaging with CSF biomarkers in monitoring the progression in Alzheimer's disease. Journal of Nuclear Medicine 2015;56 Suppl 3:1569.
Chincarini 2015 {published data only}
    1. Chincarini A, Sensi F, Guerra UP, Morbelli S, Bossert I, Rei L, et al. Amyloid‐PET quantification: methods and rationale. Clinical and Translational Imaging 2015;3 Suppl(1):S20.
Chincarini 2016 {published data only}
    1. Chincarini A, Sensi F, Rei L, Bossert I, Morbelli S, Guerra UP, et al. Standardized uptake value ratio‐independent evaluation of brain amyloidosis. Journal of Alzheimer's Disease 2016;54(4):1437‐57. - PubMed
Durkanova 2015 {published data only}
    1. Durcanova B, Diaz‐Aguilar D, Parker E, Lee J, Yi L, Silverman D. Optimal strategies for using amyloid imaging and FDG PET in prognostic evaluation of mild cognitive impairment (MCI). Journal of Nuclear Medicine 2015;56 Suppl 3:192.
Fan 2015 {published data only}
    1. Fan Z, Harold D, Pasqualetti G, Williams J, Brooks DJ, Edison P. Can studies of neuroinflammation in a TSPO genetic subgroup (HAB or MAB) be applied to the entire AD cohort?. Journal of Nuclear Medicine 2015;56(5):707‐13. - PubMed
Greenia 2014 {published data only}
    1. Greenia D, Kawas C, Caunca M, Bullain S, Corrada M. PET amyloid imaging with florbetapir predicts cognitive decline in the oldest‐old. Neurology 2014;82 Suppl 10:P4.011.
Hochstetler 2014 {published data only}
    1. Hochstetler H, Wang S, Yu P, Trzepacz PT, Case M, Henley D, et al. Empirically defining trajectories of late‐life cognitive and functional decline. Alzheimer's & Dementia 2014;10 Suppl(4):687‐8. - PMC - PubMed
Joshi 2014 {published data only}
    1. Joshi A, Pontecorvo M, Navitsky MA, Kennedy IA, Mintun M, Devous MD. Measuring change in beta‐amyloid burden over time using florbetapir‐PET and a subcortical white matter reference region. Alzheimer's & Dementia 2014;10 Suppl(4):902.
Klein 2015 {published data only}
    1. Klein G, Sampat M, Staewen D, Scott D, Suhy J. Comparison of SUVR methods and reference regions in amyloid PET. Journal of Nuclear Medicine 2015;56 Suppl 3:1741.
Landau 2014 {published data only}
    1. Landau S, Fero A, Baker S, Jagust W. Modeling longitudian Florbetapir change across the disease spectrum. Alzheimer's & Dementia 2014;10 Suppl(4):P7.
Landau 2016 {published data only}
    1. Landau SM, Horng A, Fero A, Jagust WJ. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI. Neurology 2016;86(15):1377‐85. - PMC - PubMed
Lee 2015 {published data only}
    1. Lee J, Torosyan N, Dahlbom M, Silverman D. Amyloid imaging and FDG PET as predictors of subsequent cognitive decline in MCI subpopulation. Journal of Nuclear Medicine 2015;56 Suppl 3:190.
Lim 2014 {published data only}
    1. Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, et al. Effect of amyloid on memory and non‐memory decline from preclinical to clinical Alzheimer's disease. Brain 2014;137(1):221‐31. - PubMed
Manitsirikul 2015 {published data only}
    1. Manitsirikul S, Mathotaarachchi SS, Mohamedes S, Gauthier S, Beaudry T, Rosa‐Neto P. How to follow up and cluster subjects by longitudinal changes of fibrillary amyloid imaging and CSF biomarkers? A 24‐month follow up. Alzheimer's & Dementia 2015;11 Suppl(7):P19‐21.
Margolin 2013 {published data only}
    1. Margolin RA, Andrews RD, Lukic AS, Zhao X, Tudor IC, Salloway S, et al. Biomarkers and cognition in amyloid positive and amyloid‐negative ADNI‐2 MCI subjects: implications for AD therapeutic trials. Journal of Nutrition, Health & Aging 2013;17(9):795‐96.
Mathotaarachchi 2015 {published data only}
    1. Mathotaarachchi SS, Mohades S, Shin M, Beaudry T, Benedet AL, Pascoal TA, et al. Should a global or a regional measure of amyloidosis be used in a longitudinal study?. Alzheimer's & Dementia 2015;11 Suppl(7):P19.
Mattsson 2014a {published data only}
    1. Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology 2014;1(8):534‐43. - PMC - PubMed
Mattsson 2014b {published data only}
    1. Mattsson N, Insel P, Landau S, Jagust W, Shaw L, Trojanowski JQ, et al. Combining CSF AB42 and PET florbetapir to predict diagnosis, tau, atrophy, and cognition. Alzheimer's & Dementia 2014;10 Suppl(4):P174.
Mattsson 2015a {published data only}
    1. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid‐β and florbetapir imaging in Alzheimer's disease. Brain 2015;138(3):772‐83. - PMC - PubMed
Mattsson 2015b {published data only}
    1. Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M, et al. Brain structure and function as mediators of the effects of amyloid on memory. Neurology 2015;84(11):1136‐44. - PMC - PubMed
Ming 2015 {published data only}
    1. Lu M, Pontecorvo MJ, Siderowf A, Joshi AD, Devous MD, Mintun MA, et al. Prognostic value of 18F‐Florbetapir scan: a 36‐month follow up analysis using ADNI data. Clinical and Translational Imaging 2015;3 Suppl 1:S126.
Mohades 2014 {published data only}
    1. Mohades S, Mathotaarachchi SS, Parent M, Shin M, Wang S, Benedet AL, et al. Neurodegeneration and cortical atrophy in [18f] florbetapir accumulators and non‐accumulators. Alzheimer's & Dementia 2014;10 Suppl(4):P26‐7.
Morbelli 2015 {published data only}
    1. Morbelli S, Nobili F, Sensi F, Guerra U, Rei L, Bossert I, et al. SUVratio (SUVr)‐independent semiquantification of brain amyloidosis: a software‐aided integration of visual and quantitative analyses. European Journal of Nuclear Medicine and Molecular Imaging 2015;42 Suppl 1:S547.
Pascoal 2016 {published data only}
    1. Pascoal T, Benedet A, Mathotaarachchi S, Soucy JP, Beaudry T, Gauthier S, et al. Amyloidbeta and hyperphosphorylated tau synergy drives clinical progression in individuals with mild cognitive impairment. Neurology 2016;86 Suppl(16):P2.228.
Pascoal 2017 {published data only}
    1. Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimer's & Dementia 2017;13:644‐53. - PubMed
Pontecorvo 2011 {published data only}
    1. Pontecorvo MJ, Joshi A, Skovronsky D, Clark C, Mintun M. Florbetapir PET correlates with cognitive decline, PiB PET and CSF markers in the ADNI database. Alzheimer's & Dementia 2011;7 Suppl(4):S697.
Risacher 2014 {published data only}
    1. Risacher SL, Kim S, Nho KT, West JD, Petersen RC, Aisen PS, et al. Two‐year longitudinal change in amyloid deposition, glucose metabolism, and hippocampal atrophy in ADNI‐2 participants: relation to genetic risk. Alzheimer's & Dementia 2014;10 Suppl(4):P211‐12.
Shokouhi 2016 {published data only}
    1. Shokouhi S, Mckay JW, Baker SL, Kang H, Brill AB, Gwirtsman HE, et al. Reference tissue normalization in longitudinal (18)F‐florbetapir positron emission tomography of late mild cognitive impairment. Alzheimer's Research & Therapy 2016;8(1):article no 2. - PMC - PubMed
Siderowf 2013 {published data only}
    1. Siderowf A, Joshi A, Lu M, Mintun M, Pontecorvo M. Lack of substantial progression of cognitive deficits in patients with negative amyloid imaging: implications for clinical trials. Neurology 2013;80 Suppl(7):P01.016.
Teipel 2015 {published data only}
    1. Teipel SJ, Kurth J, Krause B, Grothe MJ, Alzheimer's Disease Neuroimaging Initiative. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment ‐ beyond classical regression. NeuroImage: Clinical 2015;8:583‐93. - PMC - PubMed
Toledo 2015 {published data only}
    1. Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, et al. Nonlinear association between cerebrospinal fluid and florbetapir F‐18 beta‐amyloid measures across the spectrum of Alzheimer disease. JAMA Neurology 2015;72(5):571‐81. - PMC - PubMed
Wisse 2015 {published data only}
    1. Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, et al. Suspected non‐AD pathology in mild cognitive impairment. Neurobiology of Aging 2015;36(12):3152‐62. - PMC - PubMed
Xu 2016 {published data only}
    1. Xu L, Wu X, Li R, Chen K, Long Z, Zhang J, et al. Prediction of progressive mild cognitive impairment by multi‐modal neuroimaging biomarkers. Journal of Alzheimer's Disease 2016;51(4):1045‐56. - PubMed

References to ongoing studies

JPRN‐UMIN000019926 {unpublished data only}
    1. JPRN‐UMIN000019926. Clinical and neuroimaging study on preclinical Alzheimer's disease. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000019926 (first received 1 December 2015).
NCT01325259 {unpublished data only}
    1. NCT01325259. FluoroAv45 imaging research‐in Alzheimer's disease (FAIR‐AD). clinicaltrials.gov/show/NCT01325259 (first received 29 March 2011).
NCT01554202 {unpublished data only}
    1. NCT01554202. Multi‐modal neuroimaging in Alzheimer's disease (IMAP). clinicaltrials.gov/show/NCT01554202 (first received 14 March 2012).
NCT01638949 {unpublished data only}
    1. NCT01638949. Multi‐modal neuroimaging in Alzheimer's disease (IMAP+). clinicaltrials.gov/show/NCT01638949 (first received 12 July 2012).
NCT01687153 {unpublished data only}
    1. NCT01687153. A study of brain aging in Vietnam war veterans (DOD‐ADNI). clinicaltrials.gov/show/NCT01687153 (first received 18 September 2012).
NCT01746706 {unpublished data only}
    1. NCT01746706. Can the assessment of the subhippocampal region contribute to the detection of early diagnosis of Alzheimer's disease? A validation study using PET with florbetapir (AV‐45). https://clinicaltrials.gov/show/NCT01746706 (first received 11 December 2012).
NCT02164643 {unpublished data only}
    1. NCT02164643. Longitudinal study of brain amyloid imaging in MEMENTO (MEMENTOAmyGing). clinicaltrials.gov/show/NCT02164643 (first received 16 June 2014).
NCT02330510 {unpublished data only}
    1. NCT02330510. Amyloid and glucose PET imaging in Alzheimer and vascular cognitive impairment patients with significant white matter disease (MITNEC C6). clinicaltrials.gov/show/NCT02330510 (first received 5 January 2015).
NCT02343757 {unpublished data only}
    1. NCT02343757. Alzheimer's disease imaging with PET/MRI ‐ beta‐amyloid. clinicaltrials.gov/show/NCT02343757 (first received 22 January 2015).
NCT02854033 {unpublished data only}
    1. NCT02854033. Alzheimer's disease neuroimaging initiative 3 (ADNI3) protocol. clinicaltrials.gov/show/NCT02854033 (first received 3 August 2016).

Additional references

Albert 2011
    1. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):270‐9. - PMC - PubMed
Alzheimer's Association 2010
    1. Alzheimer's Association. Changing the trajectory of Alzheimer's disease: a national imperative. http://www.alzheimersreadingroom.com/2010/05/changing‐trajectory‐of‐alzh... (first accessed prior to 12 October 2017).
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
Archer 2015
    1. Archer HA, Smailagic N, John C, Holmes RB, Takwoingi Y, Coulthard EJ, et al. Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD010896.pub2] - DOI - PMC - PubMed
Arevalo‐Rodriguez 2015
    1. Arevalo‐Rodriguez I, Smailagic N, Figuls MRI, Ciapponi A, Sanchez‐Perez E, Giannakou A, et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2] - DOI - PMC - PubMed
Bossuyt 2008
    1. Bossuyt PM, Leeflang MM, editor(s). Chapter 6: Developing criteria for including studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 (updated September 2008). The Cochrane Collaboration, 2008. Available from srdta.cochrane.org.
Boxer 2005
    1. Boxer AL, Miller BL. Clinical features of frontotemporal dementia. Alzheimer Disease and Associated Disorders 2005;19(Suppl 1):S3‐6. - PubMed
Brun 1994
    1. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416‐8. - PMC - PubMed
Bruscoli 2004
    1. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. International Psychogeriatrics 2004;16(2):129‐40. - PubMed
Caroli 2015
    1. Caroli A, Prestia A, Wade S, Chen K, Ayutyanont N, Landau SM, et al. Alzheimer disease biomarkers as outcome measures for clinical trials in MCI. Alzheimer Disease and Associated Disorders 2015;29(2):101‐9. - PMC - PubMed
Chan 2014
    1. Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011414] - DOI - PMC - PubMed
Choi 2009
    1. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F‐AV‐45: a PET agent for Abeta plaques in the brain. Journal of Nuclear Medicine 2009;50(11):1887‐94. - PMC - PubMed
Clark 2011
    1. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir‐PET for imaging beta‐amyloid pathology. JAMA 2011;305(3):275‐83. - PMC - PubMed
Clark 2012
    1. Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid‐β plaques: a prospective cohort study. Lancet Neurology 2012;11(8):669‐78. - PubMed
CMS 2013
    1. Centers for Medicare & Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG‐00431N). www.cms.gov/medicare‐coverage‐database/details/nca‐decision‐memo.aspx?NC... (accessed 08/10/2015).
Cordella 2013
    1. Cordella CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimer's & Dementia 2013;9(2):141‐50. - PubMed
Creavin 2016
    1. Creavin S, Wisniewski S, Noel‐Storr A, Trevelyan C, Hampton T, Rayment D, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD011145.pub2] - DOI - PMC - PubMed
Davis 2013
    1. Davis DHJ, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer’s disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010460] - DOI - PMC - PubMed
Davis 2015
    1. Davis DHJ, Creavin ST, Yip JLY, Noel‐Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2] - DOI - PMC - PubMed
De la Torre 2004
    1. Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurology 2004;3(3):184‐90. - PubMed
Dubois 2014
    1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. Lancet Neurology 2014;13(6):614‐29. - PubMed
Elias‐Sonnenschein 2014a
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a community setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010948] - DOI
Elias‐Sonnenschein 2014b
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a primary care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010949] - DOI
Elias‐Sonnenschein 2014c
    1. Elias‐Sonnenschein LS, Viechtbauer W, Ramakers I, Ukoumunne O, Verhey FRJ, Visser PJ. APOE‐ϵ4 allele for the diagnosis of Alzheimer's and other dementia disorders in people with mild cognitive impairment in a secondary care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010950] - DOI
EMA 2013
    1. European Medicines Agency. Assessment report. Amyvid. International non‐proprietary name: florbetapir (18F) Procedure No. EMEA/H/C/002422. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Public_assessment_r... (accessed 8th April 2015).
Espinosa 2013
    1. Espinosa A, Alegret M, Valero S, Vinyes‐Junque G, Hernandez I, Mauleon A, et al. A longitudinal follow‐up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. Journal of Alzheimer’s Disease 2013;34(3):769‐80. - PubMed
Fage 2015
    1. Fage BA, Chan CCH, Gill SS, Noel‐Storr AH, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD010860.pub2] - DOI - PubMed
FDA 2013
    1. Food, Drug Administration. Amyvid. www.accessdata.fda.gov/drugsatfda_docs/label/2013/202008s020lbl.pdf (accessed 8 April 2015).
Filippini 2012
    1. Filippini G, Casazza G, Bellatorre AG, Lista C, Duca P, Beecher D, et al. The role of MRI in the early diagnosis of Alzheimer’s disease or other dementias in persons with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009628] - DOI
Garcia‐Alloza 2011
    1. Garcia‐Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C, et al. Cerebrovascular lesions induce transient β‐amyloid deposition. Brain 2011;134(12):3697‐707. - PMC - PubMed
Gelber 2012
    1. Gelber RP, Launer LJ, White LR. The Honolulu‐Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment. Current Alzheimer Research 2012;9(6):664‐72. - PMC - PubMed
Geslani 2005
    1. Geslani DM, Tierney MC, Herrmann N, Szalai JP. Mild cognitive impairment: an operational definition and its conversion rate to Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2005;19(5‐6):383‐9. - PubMed
Goedert 2006
    1. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006;314(5800):777‐81. - PubMed
Gurol 2016
    1. Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, et al. Florbetapir‐PET to diagnose cerebral amyloid angiopathy: a prospective study. Neurology 2016;87(19):2043‐9. - PMC - PubMed
Hampel 2012
    1. Hampel H, Lista S, Khachaturian Z. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimer's & Dementia 2012;8(4):312‐36. - PubMed
Harrison 2014
    1. Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a general practice (primary care) setting. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010771.pub2] - DOI - PubMed
Harrison 2015
    1. Harrison JK, Fearon P, Noel‐Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010772.pub2] - DOI - PubMed
Hendry 2014
    1. Hendry K, Lees RA, McShane R, Noel‐Storr AH, Stott DJ, Quinn TJ. AD‐8 for diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011121] - DOI - PMC - PubMed
Herscovitch 2015
    1. Herscovitch P. Regulatory approval and insurance reimbursement: the final steps in clinical translation of amyloid brain imaging. Clinical and Translational Imaging 2015;3:75‐7.
Heyden 2013
    1. Hayden EY, Teplow DB. Amyloid β‐protein oligomers and Alzheimer’s disease. Alzheimer's Research & Therapy 2013;5(5):1‐11. - PMC - PubMed
Hyman 2012
    1. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging‐Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimer's & Dementia 2012;8(1):1‐13. - PMC - PubMed
ICD‐10
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD‐10 Version: 2010). apps.who.int/classifications/icd10/browse/2010/en (accessed 29 January 2015).
Jack 2013
    1. Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology 2013;12(2):207‐16. - PMC - PubMed
Jellinger 2006
    1. Jellinger K. Clinicopathological analysis of dementia disorders in the elderly ‐ update. Journal of Alzheimer's Disease 2006;9(Supplement 3):61‐70. - PubMed
Johnson 2013
    1. Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine 2013;54(3):476‐90. - PubMed
Knottnerus 2002
    1. Knottnerus JA, Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ 2002;324(7335):477‐80. - PMC - PubMed
Kobylecki 2015
    1. Kobylecki C, Langheinrich T, Hinz R, Vardy ER, Brown G, Martino ME, et al. 18F‐Florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. Journal of Nuclear Medicine 2015;56(3):386‐91. - PubMed
Kokkinou 2014
    1. Kokkinou M, Smailagic N, Noel‐Storr AH, Hyde C, Ukoumunne O, Worrall RE, et al. Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010945] - DOI - PMC - PubMed
Landau 2012
    1. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology 2012;72(4):578‐86. - PMC - PubMed
Landau 2013
    1. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid. Annal of Neurology 2013;74(6):826‐36. - PMC - PubMed
Lees 2014
    1. Lees RA, Stott DJ, McShane R, Noel‐Storr AH, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011333] - DOI - PMC - PubMed
Lin 2010
    1. Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole‐body biodistribution and brain PET imaging with [18F]AV‐45, a novel amyloid imaging agent ‐ a pilot study. Nuclear Medicine and Biology 2010;37(4):497‐508. - PubMed
Lundh 2017
    1. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub2] - DOI - PMC - PubMed
Ma 2014
    1. Ma Y, Zhang S, Li J, Zheng DM, Guo Y, Feng J, et al. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow‐up: a meta‐analysis. Medicine 2014;93(27):1‐12. - PMC - PubMed
Martínez 2016
    1. Martínez G, Flicker L, Vernooij RWM, Fuentes Padilla P, Zamora J, Figuls MRI, et al. 18F PET ligands for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD012216] - DOI
Matthews 2008
    1. Matthews FE, Stephan BC, McKeith IG, Bond J, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Two‐year progression from mild cognitive impairment to dementia: to what extent do different definitions agree?. Journal of the American Geriatrics Society 2008;56(8):1424‐33. - PubMed
Mattsson 2009
    1. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302(4):385‐93. - PubMed
McCleery 2015
    1. McCleery J, Morgan S, Bradley KM, Noel‐Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010633.pub2] - DOI - PMC - PubMed
McKeith 1996
    1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47(5):1113‐24. - PubMed
McKeith 2005
    1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65(12):1863‐72. - PubMed
McKhann 1984
    1. McKhann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34(7):939‐44. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011;7(3):263‐9. - PMC - PubMed
Mitchell 2009
    1. Mitchell AJ, Shiri‐Feshki M. Rate of progression of mild cognitive impairment to dementia ‐ meta‐analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 2009;119(4):252‐65. - PubMed
Morris 1993
    1. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43(11):2412‐4. - PubMed
NAO 2007
    1. National Audit Office. Improving services and support for people with dementia. Report by the Comptroller and Auditor General. HC 604 Session General 2006‐2007. 4 July 2007. www.nao.org.uk/wp‐content/uploads/2007/07/0607604.pdf (accessed 25th March 2015).
Neary 1998
    1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51(6):1546‐54. - PubMed
NICE 2006
    1. National Institute for Health Care Excellence. Dementia: supporting people with dementia and their carers in health and social care. NICE guidelines [CG42]. www.nice.org.uk/guidance/cg42 (accessed 17th April 2015).
Noel‐Storr 2013
    1. Noel‐Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P, et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimer's & Dementia 2013;9(3):e96‐105. - PubMed
Noel‐Storr 2014
    1. Noel‐Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, et al. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. Neurology 2014;83(4):364‐73. - PMC - PubMed
Okello 2007
    1. Okello A, Edison P, Archer H, Hinz R, Fox N, Kennedy AM, et al. Amyloid deposition and cerebral glucose metabolism in mild cognitive impairment: a longitudinal 11C‐PIB and 18F‐FDG PET study. Journal of Neurology, Neurosurgery, and Psychiatry 2007;78(2):219‐20.
Petersen 1999
    1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999;56(3):303‐8. - PubMed
Petersen 2004
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256(3):183‐94. - PubMed
Petersen 2009
    1. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ, et al. Mild cognitive impairment: ten years later. Archives of Neurology 2009;66(12):1447‐55. - PMC - PubMed
Quinn 2014
    1. Quinn TJ, Fearon P, Noel‐Storr AH, Young C, McShane R, Stott DJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within community dwelling populations. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD010079.pub2] - DOI - PubMed
Rascovsky 2011
    1. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456‐77. - PMC - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Richard 2012
    1. Richard E, Schmand B, Eikelenboom P, Westendorp RG, Gool WA. The Alzheimer myth and biomarker research in dementia. Journal of Alzheimer's Disease: JAD 2012;31(Suppl 3):S203‐9. - PubMed
Ritchie 2013
    1. Ritchie C, Smailagic N, Ladds EC, Noel‐Storr AH, Ukoumunne O, Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD010803] - DOI - PMC - PubMed
Ritchie 2014
    1. Ritchie C, Smailagic N, Noel‐Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD008782.pub4] - DOI - PMC - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology 1993;43(2):250‐60. - PubMed
Royall 2014
    1. Royall DR, Palmer RF. The temporospatial evolution of neuritic plaque‐related and independent tauopathies: implications for dementia staging. Journal of Alzheimer’s Disease 2014;40(3):541‐9. - PMC - PubMed
Savva 2009
    1. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C, Medical Research Council Cognitive Function and Ageing Study. Age, neuropathology, and dementia. The New England Journal of Medicine 2009;360(22):2302‐9. - PubMed
Schneider 2007
    1. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community‐dwelling older persons. Neurology 2007;69(24):2197‐204. - PubMed
Schneider 2009
    1. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of neurology 2009;66(2):200‐8. - PMC - PubMed
Seitz 2014
    1. Seitz DP, Fage BA, Chan CCH, Gill SS, Herrmann N, Smailagic N, et al. Mini‐Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a primary care setting. Cochrane Database of Systematic Reviews 2014, Issue 12. [DOI: 10.1002/14651858.CD011415] - DOI - PMC - PubMed
Selkoe 2016
    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine 2016;8(6):595‐608. - PMC - PubMed
Serrano‐Pozo 2013
    1. Serrano‐Pozo A, Qian J, Monsell SE, Frosch MP, Betensky RA, Hyman BT. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology 2013;72(12):1182‐92. - PMC - PubMed
Siderowf 2014
    1. Siderowf A, Pontecorvo MJ, Shill HA, Mintun MA, Arora A, Joshi AD, et al. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F‐AV‐133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC neurology [electronic resource] 2014;14:1‐9. - PMC - PubMed
Smailagic 2015
    1. Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. 18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010632.pub2] - DOI - PMC - PubMed
Sperling 2011
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia: the Journal of the Alzheimer's Association 2011;7(3):280‐92. - PMC - PubMed
Visser 2006
    1. Visser PJ, Kester A, Jolles J, Verhey F. Ten‐year risk of dementia in subjects with mild cognitive impairment. Neurology 2006;67(7):1201‐7. - PubMed
White 2009
    1. White L. Brain lesions at autopsy in older Japanese‐American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu‐Asia aging study. Journal of Alzheimer's Disease: JAD 2009;18(3):713‐25. - PubMed
Whiting 2011
    1. Whiting PF, Rutjes AWS, Westwood ME, Mallet S, Deeks JJ, Reitsma JB. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529‐36. - PubMed
WHO 2012
    1. World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. 2012. http://www.who.int/mental_health/publications/dementia_report_2012/en/. World Health Organization, (accessed 23th September 2015).
Winblad 2004
    1. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment‐‐beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. Journal of Internal Medicine 2004;256(3):240‐6. - PubMed
Wolz 2016
    1. Wolz R, Schwarz AJ, Gray KR, Yu P, Hill DL, Alzheimer's Disease Neuroimaging Initiative. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. Neurology 2016;87(12):1235‐41. - PMC - PubMed
Wong 2010
    1. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F‐AV‐45 (Florbetapir F18). Journal of Nuclear Medicine 2010;51(6):913‐20. - PMC - PubMed
Zhang 2014
    1. Zhang S, Smailagic N, Hyde C, Noel‐Storr AH, Takwoingi Y, McShane R, et al. 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010386.pub2] - DOI - PMC - PubMed

Publication types